The US Food and Drug Administration (FDA) recently approved a 2.4 mg/week subcutaneous dose of the GLP-1 receptor agonist semaglutide for weight loss in people who have obesity, or overweight with a related health complication. Semaglutide is already in use to treat type 2 diabetes, but the approval for this drug, to be sold under the brand name Wegovy™, is for a formulation more than double the standard dose for diabetes treatment. Read more